Jim Cramer highlighted Moderna's recent progress during a segment on CNBC, noting that the company has surged nearly 150% this year, making it one of the top performers in the S&P 500. Despite this impressive rise, Moderna's stock remains significantly below its pandemic peak of $484.
Cramer emphasized that for the first time in years, Moderna is presenting a clear roadmap to profitability, particularly through its expanding cancer pipeline, which includes therapies in mid and late-stage trials for various cancers. He expressed particular excitement about upcoming results from a study combining Moderna's Intismeran with Merck's Keytruda for melanoma treatment.
Additionally, Moderna's advancements in other vaccine areas, such as a recommended FDA approval for its flu vaccine and the European Commission's approval of a combination Covid and flu vaccine, further bolster its growth prospects.
Cramer advised investors to be patient and wait for a pullback before buying, indicating that while Moderna has a bright future, it may take time to realize its full potential